

Long COVID Dashboard: Prevalence (ONS prevalence estimates)







Long COVID Dashboard: Key statistics Post hospitalisation

ONS and University of Leicester: Epidemiology of post-COVID syndrome following hospitalisation with coronavirus

A large study (n=47,780 participants in hospital with COVID-19 and discharged alive by 31 August 2020 matched to controls) led by the ONS and the University of Leicester found that Covid-19 hospital admission was associated with increased risk of re-admission and death following discharge. Nearly one third of people were re-admitted and more than 1 in 10 died. Rates of post-discharge multi-organ dysfunction were elevated in individuals with COVID-19 compared to matched controls (general population). Diabetes and major adverse cardiac events (MACE) were common.

Open Safely: Rates of serious clinical outcomes in survivors of hospitalisation with COVID-19

The rate of cardiometabolic and pulmonary events in COVID-19 patients discharged from hospitalisation was elevated in a similar manner to patients discharged from hospitalisation with prepandemic pneumonia, with some outcomes observed to have a slightly higher rate in the COVID-19 population



Long COVID Dashboard: Research (NIHR/UKRI Joint Research call on LONG COVID)

NIHR/UKRI Joint Research call on LONG COVID in non-hospitalised patients (4 studies, Irreleva

Applications were considered by an independent panel on 22 January which recommended the following four studies for funding, at a cost of approximately £18.65 million

		(<u>)</u>
REACT Long COVID (REACT-LC)	Led by Professor Paul Elliott, Imperial College London	Irrel hillion over 3 years
Therapies for Long COVID in non-hospitalised individuals: From symptoms, patient-reported outcomes and immunology to targeted therapies (The TLC Study),	Led by Dr Shamil Haroon, University of Birmingham	Irrel nillion over 2 years
Characterisation, determinants, mechanisms and consequences of the long-term effects of COVID-19: providing the evidence base for health care services	Led by Professor Nishi Chaturvedi, University College London	Irrel nillion over 3 years
Non-hospitalised Children & young people (CYP) with Long Covid (The CLoCk Study	Led by Professor Sir Terence Stephenson, UCL Great Ormond Street Institute of Child Health	Irrel fillion over 3 years
		6

Long COVID Dashboard: Research (other DH/NIHR/UKRI research)

NIHR/UKRI Rolling Research call on LONG COVID (3 relevant studies, Irrelev		
Post-hospitalisation COVID-19 study: a national consortium to understand and improve long-term health outcomes (PHOSP-COVID The PHOSP-COVID national consortium and research platform aims to understand and improve long-term outcomes for survivors following hospitalisation with COVID-19. Update: The total recruitment figures for 1st Feb 2021 are 2,038 (tier 1: 656, tier 2: 1,382):The mean age is 60, with an age range of 21-91. The study population was found to be 72% white, 15% Asian, 7% Black, and 7% other	Led by Professor Chris Brightling, University of Leicester	Irrel
COVID-19: Clinical Neuroscience Study (COVID-CNS) The study will conduct a case control study to determine the phenotypes and genotypes of patients with these complications relative to 500 previously hospitalised controls.	led by Dr Benedict Michael, University of Liverpool, and Professor Gerome Breen, Kings College London	Irreleva
REACT-GE: Multi-omics to identify biological pathways underlying severity of SARS-CoV-2 infection Researchers will delineate biological pathways that are protective of or deleterious to the response to SARS- CoV-2 infection that may identify novel targets for treatment and ultimately prevention of the disease (e.g. vaccine response).	Led by Professor Paul Elliott, Imperial College London	Irrele
Note, in addition the ISARIC – Corovavirus Clinical Characterisation Consortium (ISARIC-4X) may be redesigned for Long COVID, it provides underpinning information on hospitalised patients and they are now doing Funding: Lerol, ed by: Dr Kenneth Baillie (Edinburgh) Prof Peter Openshaw (Imperial) and Prof Calum Semp	levant. while the award was r g immunological follow-up on j le (Liverpool).	ot patients.

Long COVID Dashboard: Research (Other research funded by UKRI				
Other research funded by UKRI (3 studies, Irreleva				
UK Interstitial Lung Disease Long-COVID19 study (UKILD-Long COVID): understanding the burden of Interstitial Lung Disease in Long COVID	Led by Professor Gisli Jenkins, University of Nottingham	vant		
The study will aim to understand the burden and natural history of Interstitial Lung Disease (ILD) following COVID in hospitalised and non-hospitalised patients, focusing primarily on the imaging and mechanisms of ILD evolution in both the cross sectional and longitudinal analysis.	Funded through the UKRI Agile call			
Dissecting innate immune determinants of severity and resolution in a longitudinal study of COVID-19	Led by Dr Mariola Kurowska- Stolarska, University of Glasgow	Irrele		
This project will explore the hypothesis that myeloid cells from patients with severe COVID-19 have impaired endogenous homeostatic mechanisms that limit the pathogenic monocyte and lung macrophage activation in milder forms of disease.	Funded through the UKRI Agile call			
Understanding the impact of Covid-19 on long term health to inform the design of mitigating policies	Led by Dr Nish Chaturvedi, UCL	Irrelev		
This study will generate greater understanding of risk factors related to Covid-19 outcomes (e.g. from individual risk factors to wider environmental risk factors), as well as information on the burden of both short- and long-term health and wider outcomes related to Covid-19 and interventions.	funded by UKRI through the National Core Studies Longitudinal Health & Wellbeing programme			
 Information not in the public domain: studies yet to be awarded and information shared in comformation shared in comformation of post-COVID fatigue, led by Dr Demetris Soteropoulos, OpenSAFELY, ISARIC, PHOSP: tracking consequences of COVID-19 infection across UK prid Goldacre, University of Oxford - Irrele 	idence by UKRI Newcastle University [[[rrele] mary and secondary care, led by [Dr Ben		
		8		

Long COVID Dashboard: Emerging research/news stories

WHO Director-General's opening remarks at the media briefing on COVID-19 – 12 February 2021

- WHO will focus on recognition, research and rehabilitation and has described Long COVID as Post-COVID Condition.
- WHO released a case reporting form that will allow more data to be collected on long COVID in a standardised way. This will help to improve the understanding, surveillance and clinical management of the condition

WHO Director-General's opening remarks at the media briefing on COVID-19 - 12 February 2021

Researchers examined more than 4 million blood cells of 17 COVID-19 patients hospitalised at the time of sample collection, 24 from a control group and then 14 people who had recovered (on average 7 months after hospitalisation) and found significant changes in blood cells. While some of the changes recovered to normal values after hospitalisation, others persisted for months after hospital discharge, evidencing the long-term imprint of COVID. The authors hypothesise that persisting changes of blood cell physical phenotypes could contribute to impairment of circulation and oxygen delivery in some patients with Long COVID.

Physical phenotype of blood cells is altered in COVID-19 | bioRxiv

In a study of 207 SARS-CoV2-infected individuals with a range of severities followed over 12 weeks from symptom onset, researchers suggest that an early robust immune response, without systemic inflammation, is characteristic of asymptomatic or mild disease. The research team noted alterations in many immune cell types persisted for weeks or even months after infection and speculated that immunometabolic inflammatory changes and unresolved immune cell defects could contribute to Long COVID.

Early immune pathology and persistent dysregulation characterise severe COVID-19 | medRxiv

Long COVID Dashboard: Forward view

Cabinet Office Roadmap	NHSEI updated publication
Status: Due for publication on 22 February 2021	Date: 25 March 2021
The Taskforce has submitted a high-level paragraph outlining Long COVID. We do not yet know if the paragraph on Long COVID will remain in the document.	Status: NHSEI are working to produce a board paper which will update the Five Point Plan. We will want to review drafts and draw up a communications plan.
February Ministerial roundtable	March Ministerial roundtable
Status: 24 February 2021	Status: Date to be confirmed
Topic: Tech	Topic: To be confirmed
Speakers: ONS, NHSRI, National Voices, NHSX	Speakers: To be confirmed
	10